Is PRAX or IMNM more profitable?

Praxis Precision Medicines' return on equity of -43.02% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Praxis Precision Medicines N/A -43.02% -40.22% Immunome N/A -51.15% -47.32%

Does the media prefer PRAX or IMNM?

In the previous week, Praxis Precision Medicines had 23 more articles in the media than Immunome. MarketBeat recorded 26 mentions for Praxis Precision Medicines and 3 mentions for Immunome. Immunome's average media sentiment score of 0.25 beat Praxis Precision Medicines' score of -0.08 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 3 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Immunome 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, CYTK or IMNM?

Immunome has lower revenue, but higher earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cytokinetics $88.04M 101.03 -$784.96M -$6.84 N/A Immunome $6.94M 303.20 -$212.39M -$2.38 N/A

Is CYTK or IMNM more profitable?

Immunome has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Cytokinetics -784.02% N/A -52.86% Immunome N/A -51.15% -47.32%

Does the media favor CYTK or IMNM?

In the previous week, Cytokinetics had 7 more articles in the media than Immunome. MarketBeat recorded 10 mentions for Cytokinetics and 3 mentions for Immunome. Immunome's average media sentiment score of 0.25 beat Cytokinetics' score of 0.12 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunome 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, IMNM or KRYS?

Krystal Biotech has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunome $6.94M 303.20 -$212.39M -$2.38 N/A Krystal Biotech $389.13M 22.80 $204.83M $7.48 40.24

Does the media refer more to IMNM or KRYS?

In the previous week, Krystal Biotech had 5 more articles in the media than Immunome. MarketBeat recorded 8 mentions for Krystal Biotech and 3 mentions for Immunome. Krystal Biotech's average media sentiment score of 0.58 beat Immunome's score of 0.25 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Krystal Biotech 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, NUVL or IMNM?

Immunome has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvalent N/A N/A -$425.38M -$6.06 N/A Immunome $6.94M 303.20 -$212.39M -$2.38 N/A

Is NUVL or IMNM more profitable?

Nuvalent's return on equity of -40.11% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Nuvalent N/A -40.11% -35.43% Immunome N/A -51.15% -47.32%

Does the media prefer NUVL or IMNM?

In the previous week, Nuvalent had 5 more articles in the media than Immunome. MarketBeat recorded 8 mentions for Nuvalent and 3 mentions for Immunome. Immunome's average media sentiment score of 0.25 beat Nuvalent's score of 0.03 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Immunome 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, IBRX or IMNM?

Immunome has lower revenue, but higher earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $113.29M 63.97 -$351.40M -$0.85 N/A Immunome $6.94M 303.20 -$212.39M -$2.38 N/A

Does the media prefer IBRX or IMNM?

In the previous week, ImmunityBio had 5 more articles in the media than Immunome. MarketBeat recorded 8 mentions for ImmunityBio and 3 mentions for Immunome. Immunome's average media sentiment score of 0.25 beat ImmunityBio's score of -0.19 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Immunome 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Immunome (IMNM) Competitors

$18.58 -1.10 (-5.59%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$18.88 +0.30 (+1.62%)

As of 06/5/2026 05:47 PM Eastern

Compare

IMNM vs. PRAX, CYTK, KRYS, NUVL, and IBRX

Should you buy Immunome stock or one of its competitors? MarketBeat compares Immunome with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immunome include Praxis Precision Medicines (PRAX), Cytokinetics (CYTK), Krystal Biotech (KRYS), Nuvalent (NUVL), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry.

How does Immunome compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Immunome (NASDAQ:IMNM) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Immunome has lower revenue, but higher earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	828.25	-$303.27M	-$13.37	N/A
Immunome	$6.94M	303.20	-$212.39M	-$2.38	N/A

Praxis Precision Medicines presently has a consensus price target of $572.72, indicating a potential upside of 125.48%. Immunome has a consensus price target of $33.17, indicating a potential upside of 78.51%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts clearly believe Praxis Precision Medicines is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

In the previous week, Praxis Precision Medicines had 23 more articles in the media than Immunome. MarketBeat recorded 26 mentions for Praxis Precision Medicines and 3 mentions for Immunome. Immunome's average media sentiment score of 0.25 beat Praxis Precision Medicines' score of -0.08 indicating that Immunome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	3 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunome	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Praxis Precision Medicines has a beta of 2.71, indicating that its stock price is 171% more volatile than the broader market. Comparatively, Immunome has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market.

Praxis Precision Medicines' return on equity of -43.02% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Immunome	N/A	-51.15%	-47.32%

67.8% of Praxis Precision Medicines shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 2.7% of Praxis Precision Medicines shares are owned by insiders. Comparatively, 7.2% of Immunome shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Praxis Precision Medicines beats Immunome on 11 of the 16 factors compared between the two stocks.

How does Immunome compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Immunome (NASDAQ:IMNM) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Immunome has lower revenue, but higher earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	101.03	-$784.96M	-$6.84	N/A
Immunome	$6.94M	303.20	-$212.39M	-$2.38	N/A

In the previous week, Cytokinetics had 7 more articles in the media than Immunome. MarketBeat recorded 10 mentions for Cytokinetics and 3 mentions for Immunome. Immunome's average media sentiment score of 0.25 beat Cytokinetics' score of 0.12 indicating that Immunome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunome	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

44.6% of Immunome shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by insiders. Comparatively, 7.2% of Immunome shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cytokinetics has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market. Comparatively, Immunome has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market.

Immunome has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Immunome	N/A	-51.15%	-47.32%

Cytokinetics currently has a consensus price target of $99.30, indicating a potential upside of 38.92%. Immunome has a consensus price target of $33.17, indicating a potential upside of 78.51%. Given Immunome's higher probable upside, analysts plainly believe Immunome is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Summary

Immunome beats Cytokinetics on 11 of the 17 factors compared between the two stocks.

How does Immunome compare to Krystal Biotech?

Immunome (NASDAQ:IMNM) and Krystal Biotech (NASDAQ:KRYS) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

Krystal Biotech has a net margin of 53.92% compared to Immunome's net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.15%	-47.32%
Krystal Biotech	53.92%	19.25%	17.62%

Immunome presently has a consensus target price of $33.17, suggesting a potential upside of 78.51%. Krystal Biotech has a consensus target price of $324.11, suggesting a potential upside of 7.68%. Given Immunome's stronger consensus rating and higher probable upside, analysts plainly believe Immunome is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

44.6% of Immunome shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 7.2% of Immunome shares are owned by insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Krystal Biotech had 5 more articles in the media than Immunome. MarketBeat recorded 8 mentions for Krystal Biotech and 3 mentions for Immunome. Krystal Biotech's average media sentiment score of 0.58 beat Immunome's score of 0.25 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Krystal Biotech	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunome has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

Krystal Biotech has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	303.20	-$212.39M	-$2.38	N/A
Krystal Biotech	$389.13M	22.80	$204.83M	$7.48	40.24

Summary

Krystal Biotech beats Immunome on 11 of the 16 factors compared between the two stocks.

How does Immunome compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and Immunome (NASDAQ:IMNM) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

In the previous week, Nuvalent had 5 more articles in the media than Immunome. MarketBeat recorded 8 mentions for Nuvalent and 3 mentions for Immunome. Immunome's average media sentiment score of 0.25 beat Nuvalent's score of 0.03 indicating that Immunome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Immunome	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nuvalent presently has a consensus price target of $141.24, indicating a potential upside of 55.29%. Immunome has a consensus price target of $33.17, indicating a potential upside of 78.51%. Given Immunome's higher probable upside, analysts plainly believe Immunome is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.94
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Nuvalent has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Immunome has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market.

97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 5.0% of Nuvalent shares are owned by insiders. Comparatively, 7.2% of Immunome shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Nuvalent's return on equity of -40.11% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Immunome	N/A	-51.15%	-47.32%

Immunome has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Immunome	$6.94M	303.20	-$212.39M	-$2.38	N/A

Summary

Immunome beats Nuvalent on 8 of the 15 factors compared between the two stocks.

How does Immunome compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Immunome (NASDAQ:IMNM) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

Immunome has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
Immunome	N/A	-51.15%	-47.32%

ImmunityBio has a beta of 0.03, suggesting that its share price is 97% less volatile than the broader market. Comparatively, Immunome has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market.

ImmunityBio currently has a consensus price target of $14.20, indicating a potential upside of 105.20%. Immunome has a consensus price target of $33.17, indicating a potential upside of 78.51%. Given ImmunityBio's higher possible upside, research analysts plainly believe ImmunityBio is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

In the previous week, ImmunityBio had 5 more articles in the media than Immunome. MarketBeat recorded 8 mentions for ImmunityBio and 3 mentions for Immunome. Immunome's average media sentiment score of 0.25 beat ImmunityBio's score of -0.19 indicating that Immunome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Immunome	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 69.5% of ImmunityBio shares are owned by company insiders. Comparatively, 7.2% of Immunome shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Immunome has lower revenue, but higher earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	63.97	-$351.40M	-$0.85	N/A
Immunome	$6.94M	303.20	-$212.39M	-$2.38	N/A

Summary

Immunome beats ImmunityBio on 10 of the 16 factors compared between the two stocks.

Get Immunome News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMNM vs. The Competition

Export

Metric	Immunome	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.10B	$3.34B	$6.66B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.56%
P/E Ratio	-7.81	18.69	24.03	23.62
Price / Sales	303.20	300.27	513.89	111.51
Price / Cash	N/A	51.45	26.99	37.22
Price / Book	3.23	7.97	10.24	6.66
Net Income	-$212.39M	$23.89M	$3.57B	$337.55M
7 Day Performance	-14.89%	-6.96%	-1.28%	-2.52%
1 Month Performance	-16.27%	-2.80%	1.38%	-0.03%
1 Year Performance	103.50%	36.80%	23.93%	25.34%

Immunome Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMNM Immunome	3.6418 of 5 stars	$18.58 -5.6%	$33.17 +78.5%	+103.5%	$2.10B	$6.94M	N/A	40	News Coverage
PRAX Praxis Precision Medicines	2.8606 of 5 stars	$335.16 -4.2%	$590.11 +76.1%	+470.0%	$9.34B	N/A	N/A	110	News Coverage Analyst Forecast Analyst Revision
CYTK Cytokinetics	2.8552 of 5 stars	$73.68 -4.0%	$99.30 +34.8%	+121.3%	$9.17B	$105.82M	N/A	250
KRYS Krystal Biotech	3.0415 of 5 stars	$298.10 -3.5%	$324.11 +8.7%	+119.8%	$9.11B	$417.30M	39.85	210	News Coverage Insider Trade
NUVL Nuvalent	3.4627 of 5 stars	$93.01 -15.7%	$140.29 +50.8%	+16.6%	$8.72B	N/A	N/A	40	Analyst Forecast Insider Trade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMNM) was last updated on 6/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunome (IMNM) Competitors

IMNM vs. PRAX, CYTK, KRYS, NUVL, and IBRX

How does Immunome compare to Praxis Precision Medicines?

Summary

How does Immunome compare to Cytokinetics?

Summary

How does Immunome compare to Krystal Biotech?

Summary

How does Immunome compare to Nuvalent?

Summary

How does Immunome compare to ImmunityBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNM vs. The Competition

Immunome Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunome (IMNM) Competitors

IMNM vs. PRAX, CYTK, KRYS, NUVL, and IBRX

How does Immunome compare to Praxis Precision Medicines?

Which has higher earnings & valuation, PRAX or IMNM?

Do analysts prefer PRAX or IMNM?

Does the media prefer PRAX or IMNM?

Which has more risk & volatility, PRAX or IMNM?

Is PRAX or IMNM more profitable?

Do institutionals & insiders have more ownership in PRAX or IMNM?

Summary

How does Immunome compare to Cytokinetics?

Which has stronger valuation and earnings, CYTK or IMNM?

Does the media favor CYTK or IMNM?

Do institutionals and insiders believe in CYTK or IMNM?

Which has more risk & volatility, CYTK or IMNM?

Is CYTK or IMNM more profitable?

Do analysts rate CYTK or IMNM?

Summary

How does Immunome compare to Krystal Biotech?

Is IMNM or KRYS more profitable?

Do analysts prefer IMNM or KRYS?

Do institutionals & insiders hold more shares of IMNM or KRYS?

Does the media refer more to IMNM or KRYS?

Which has more risk & volatility, IMNM or KRYS?

Which has preferable valuation & earnings, IMNM or KRYS?

Summary

How does Immunome compare to Nuvalent?

Does the media prefer NUVL or IMNM?

Do analysts prefer NUVL or IMNM?

Which has more risk and volatility, NUVL or IMNM?

Do institutionals and insiders have more ownership in NUVL or IMNM?

Is NUVL or IMNM more profitable?

Which has higher valuation & earnings, NUVL or IMNM?

Summary

How does Immunome compare to ImmunityBio?

Is IBRX or IMNM more profitable?

Which has more volatility & risk, IBRX or IMNM?

Do analysts recommend IBRX or IMNM?

Does the media prefer IBRX or IMNM?

Do institutionals & insiders have more ownership in IBRX or IMNM?

Which has higher earnings & valuation, IBRX or IMNM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNM vs. The Competition

Immunome Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools